Dacomitinib

Target: This ligand targets ERBB-family kinases EGFR, HER2/ERBB2, and HER4/ERBB4 in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for ERBB-family kinases EGFR, HER2/ERBB2, and HER4/ERBB4. In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings ERBB-family kinases EGFR into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• EGFR PROTAC Degradation: Dacomitinib can serve as an EGFR-binding warhead in PROTAC designs to drive ubiquitin-dependent degradation of EGFR-family kinases. By coupling EGFR engagement with an E3 ligase recruiter, researchers can evaluate whether sustained loss of receptor signaling outperforms reversible inhibition in cellular models.

• Signal Pathway Suppression: PROTACs incorporating Dacomitinib may be used to dissect EGFR-driven signaling networks, including downstream MAPK and PI3K/AKT pathways. Targeted degradation enables time-resolved studies of pathway shutdown, receptor turnover kinetics, and compensatory feedback, supporting mechanistic comparisons with kinase inhibition-only strategies.

• Resistance Mechanism Studies: Dacomitinib-based PROTACs are useful for probing resistance to EGFR kinase inhibitors, including alterations that reduce drug binding or alter kinase conformation. Degradation-centric approaches can test whether proteasomal removal of EGFR-family targets mitigates resistant phenotypes and clarifies the role of specific EGFR variants.

• EGFR Family Targeting: Dacomitinib’s affinity profile across EGFR/HER family members can be leveraged to design PROTACs that selectively degrade one or multiple related kinases. This supports experimental mapping of target selectivity, co-degradation effects, and relative contributions of EGFR versus HER2/HER4 to observed phenotypes.

• Proteasome-Dependent Validation: Researchers can use Dacomitinib-based PROTACs to establish degradation mechanisms by employing proteasome and ubiquitination perturbation experiments. Measuring EGFR-family protein loss alongside ubiquitination status and downstream signaling readouts helps confirm that the observed effects are driven by targeted protein degradation rather than transcriptional or off-target toxicity.

Dacomitinib is an EGFR-family kinase ligand containing a covalent acrylamide warhead. It may guide EGFR-directed degrader design when the covalent binding element and quinazoline recognition core are preserved.

Structure: Dacomitinib is an EGFR-family kinase ligand containing a quinazoline core, chloro-fluoro anilino substituent, methoxy group, and an acrylamide side chain attached to a piperidine-containing amine. The acrylamide provides an electrophilic Michael acceptor associated with covalent kinase engagement.

Reactivity: For PROTAC design, the quinazoline core and acrylamide warhead should be preserved if covalent EGFR binding is desired. Linker installation should focus on the piperidine side-chain region or a validated solvent-exposed vector rather than the anilino quinazoline pharmacophore. Alkyl, PEG, amide, carbamate, or tertiary-amine-compatible linkers may be paired with CRBN, VHL, or IAP ligands while ensuring that the acrylamide remains appropriately positioned and not prematurely consumed.